<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268147</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-1580</org_study_id>
    <nct_id>NCT04268147</nct_id>
  </id_info>
  <brief_title>Instrumented Data Exchange for Ataxia Study</brief_title>
  <acronym>IDEA</acronym>
  <official_title>APDM Instrumented Data Exchange for Ataxia (IDEA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>APDM Wearable Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is testing body-worn sensors to measure movement during simple tests of
      coordination, in order to evaluate the progression and severity of ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>iSARA</measure>
    <time_frame>2 years</time_frame>
    <description>measurements collected by wearable inertial sensors during instrumented Scale for the Assessment and Rating of Ataxia (iSARA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARA</measure>
    <time_frame>2 years</time_frame>
    <description>Scale for the Assessment and Rating of Ataxia (SARA) measurements evaluated by clinician to measure severity of spinocerebellar ataxia through coordination, speech, stance, and gait</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mFARS</measure>
    <time_frame>2 years</time_frame>
    <description>modified Friedreich's Ataxia Rating Scale (mFARS) measurements evaluated by clinician compared to measure severity of Friedreich's ataxia through coordination, speech, stance, and gait</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Life (UChicago site ONLY)</measure>
    <time_frame>2 weeks</time_frame>
    <description>APDM SmartSox technology used to measure daily life activity(movement, falls, etc.) of all University of Chicago subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ataxia App on Watch/iPhone</measure>
    <time_frame>2 years</time_frame>
    <description>Bi-weekly assessments completed on Ataxia Application for Apple Watches and iPhones. Data collected includes active monitoring of speech, stance, coordination, gait and patient-reported symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Reported Questionnaires of Health</measure>
    <time_frame>2 years</time_frame>
    <description>Activities, Balance, and Confidence (ABC) Questionnaire; EQ-5D-5L Health Questionnaire; Modified Fatigue Impact Scale (MFIS-5); Activities of Daily Living (ADLs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Falls Questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>Automatic email sent out to subjects inquiring about any falls and near falls they have experienced during the past month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Staging</measure>
    <time_frame>2 years</time_frame>
    <description>Clinician evaluates severity of ataxia symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed 25 Foot Walk</measure>
    <time_frame>2 years</time_frame>
    <description>Subjects walk for 25 feet, as quickly and safely as possible, while being timed</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Spinocerebellar Ataxia Type 6</condition>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia-1</arm_group_label>
    <description>individuals with a genetically confirmed diagnosis of SCA-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia-2</arm_group_label>
    <description>individuals with a genetically confirmed diagnosis of SCA-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia-3</arm_group_label>
    <description>individuals with a genetically confirmed diagnosis of SCA-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia-6</arm_group_label>
    <description>individuals with a genetically confirmed diagnosis of SCA-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Freidreich's Ataxia</arm_group_label>
    <description>individuals with a genetically confirmed diagnosis of FA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FA Controls</arm_group_label>
    <description>Healthy, age-matched controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCA Controls</arm_group_label>
    <description>Healthy, age-matched controls</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        ataxia clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SCA 1, 2, 3, 6, and FA with mutations in the pathogenic range confirmed from genetic
             testing

          -  SCA: aged 18-75 years

          -  FA: aged 12-30, diagnosed between ages 5-25

          -  community dwelling

          -  physically/cognitively capable of consenting/assenting and complying with the protocol
             based on investigator's judgement

          -  able to walk independently 10 feet without an assistive device

          -  able to sit or stand unassisted for 30 seconds

          -  no other neurological or musculoskeletal disorder that could affect mobility

          -  no other history of head injury, vestibular function, stroke, or other disorders that
             could affect mobility

          -  willing and able to participate in a 2-year study

          -  consent to be video recorded while performing study assessments

        Exclusion Criteria:

          -  dementia that limits subjects' ability to follow directions

          -  pain that limits mobility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hannah Casey</last_name>
    <phone>7737024610</phone>
    <email>hannahcasey@uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California-Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <email>adfisher@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Casey</last_name>
      <phone>773-702-4610</phone>
      <email>hannahcasey@uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Gomez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Iannuzzelli</last_name>
      <email>kiannuz1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Liana Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Macmore</last_name>
      <email>jmacmore@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Schmahmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

